Journal article
Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study.
- Abstract:
-
OBJECTIVE: Budesonide MMX is a novel oral formulation of budesonide that uses Multi-Matrix System (MMX) technology to extend release to the colon. This study compared the efficacy of budesonide MMX with placebo in patients with active, mild-to-moderate ulcerative colitis (UC). DESIGN: Patients were randomised 1:1:1:1 to receive budesonide MMX 9 mg or 6 mg, or Entocort EC 9 mg (budesonide controlled ileal-release capsules; reference arm) or placebo once daily for 8 weeks. The primary endpoint ...
Expand abstract
- Publication status:
- Published
Actions
Authors
Bibliographic Details
- Journal:
- Gut
- Volume:
- 63
- Issue:
- 3
- Pages:
- 433-441
- Publication date:
- 2014-03-01
- DOI:
- EISSN:
-
1468-3288
- ISSN:
-
0017-5749
- Source identifiers:
-
388248
Item Description
- Language:
- English
- Keywords:
- Pubs id:
-
pubs:388248
- UUID:
-
uuid:35d084ca-b908-4079-82b4-d0a714640c96
- Local pid:
- pubs:388248
- Deposit date:
- 2013-11-16
Terms of use
- Copyright date:
- 2014
If you are the owner of this record, you can report an update to it here: Report update to this record